Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AclarionACON -0.39%30 EV-to-EBITDA is -0.73 as of Jul. 22, 2026. GuruFocus rates ACON with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 506 Healthcare Providers & Services companies, Aclarion ranks worse than 197628.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aclarion's enterprise value is $5.83 Mil.
Aclarion's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-7.95 Mil. Therefore, Aclarion's EV-to-EBITDA for today is -0.73.
The historical rank and industry rank for Aclarion's EV-to-EBITDA or its related term are showing as below:
ACON'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.75 Med: 1.18 Max: 2.35
Current: -0.73
During the past 7 years, the highest EV-to-EBITDA of Aclarion was 2.35. The lowest was -0.75. And the median was 1.18.
ACON's EV-to-EBITDA is ranked worse than 100% of 506
companies
in the Healthcare Providers & Services industry
Industry Median: 11.075
vs ACON: -0.73
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Aclarion (NAS:ACON) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aclarion's share price for today is $2.53.
Aclarion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Aclarion's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Aclarion's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclarion EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Aclarion's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aclarion's EV-to-EBITDA falls into.
Aclarion's current Enterprise Value is $5.83 Mil.
Aclarion's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclarion (ACON) has a EV-to-EBITDA of -0.73 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aclarion. According to the industry distribution chart, Aclarion ranks #999999 out of 506 companies in the Healthcare Providers & Services industry.
Is Aclarion's EV-to-EBITDA too high?
Aclarion's current EV-to-EBITDA is -0.73. Based on the distribution chart, Aclarion ranks #999999 out of 506 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Aclarion has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aclarion's EV-to-EBITDA compare to WLSS and VYND?
According to the Healthcare Providers & Services industry distribution chart, Aclarion ranks #999999 out of 506 companies for EV-to-EBITDA. This places Aclarion in the lower half of its industry. The industry median EV-to-EBITDA is 11.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.08, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aclarion. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aclarion's current EV-to-EBITDA is -0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclarion stock overvalued right now?
Aclarion (ACON) has a current EV-to-EBITDA of -0.73. The current EV-to-EBITDA is -0.73. Aclarion's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aclarion (ACON), the current EV-to-EBITDA is -0.73 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
30GF Score
Get the complete analysis for ACON
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACON has been successfully added to your 
